Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
MRNA logo

Moderna Navigates 40% Revenue Drop as it Pivots to Oncology and Flu

MRNA10-KFiling Date: 2/20/2026
Moderna, Inc.
Description

What this story covers

Moderna's 2025 10-K details a strategic shift after a 40% revenue decline from waning COVID-19 demand. With $8.1 billion cash, the company prioritizes its late-stage pipeline in oncology, RSV, and flu to restore long-term growth.

Story snapshot

CompanyModerna, Inc.
TickerMRNA
VariantStandard detailed
Duration13:13
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001682852-26-000033
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in